Champions Oncology (FRA:2I3) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 09, 2026)


FRA:2I3 Champions Oncology Inc FRA:2I3
61 GF Score
Price €4.98
GF Value €5.46
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Champions Oncology's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:2I3 vs SEER, RLYB, FBIO: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Champions Oncology's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Margin of Safety % (DCF Earnings Based) falls into.


FRA:2I3
61GF Score
Champions Oncology Inc FRA:2I3
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Champions Oncology (FRA:2I3) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of €4.98 is trading 8.8% below its estimated GF Value™ of €5.46.

Key valuation signals for FRA:2I3:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €5.46 vs. price of €4.98 (8.8% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the FRA:2I3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Other Exchanges CSBR:USA
Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
61GF Score

Get the complete analysis for FRA:2I3

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.98
Price
€5.46
GF Value